Divestitures - Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2014	[1]	Sep. 30, 2014	[1]	Jun. 30, 2014	[1]	Mar. 31, 2014	[1]	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
(Loss) income from discontinued operations (net of tax)	$ (1,058)		$ (6,679)		$ (60,025)		$ (1,769)		$ 0	$ (69,531)	$ 4,108
Antioxidant, Ibuprofen and Propofol Assets
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net sales										154,273	222,146
(Loss) income from discontinued operations										(90,439)	5,985
Income tax (benefit) expense										(20,908)	1,877
(Loss) income from discontinued operations (net of tax)										$ (69,531)	$ 4,108

[1] Included in Loss from discontinued operations (net of tax) for the year ended December 31, 2014 is ($65.7) million related to the loss on the sale of our antioxidant, ibuprofen and propofol businesses and assets, the majority of which was recorded in the second quarter. See Note 3, “Divestitures.”